Publication | Closed Access
P0886 : Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial
38
Citations
0
References
2015
Year
Viral HepatitisAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirologyC-edge Treatment-experienced TrialG4 InfectionInfection ControlAntiviral DrugMedicineGrazoprevir/elbasvir +/- Rbv
No additional data available for this publication yet. Check back later!